47 results
PRE 14A
SYRS
Syros Pharmaceuticals Inc.
12 Apr 24
Preliminary proxy
4:30pm
director as reimbursement of an expense will not count against this limit. Exceptions to this limitation may only be made by our board of directors … in connection with regulatory compliance and any amounts paid to a non-employee director as reimbursement of an expense shall not count against
8-K
EX-4.1
SYRS
Syros Pharmaceuticals Inc.
19 Dec 23
Syros Announces Pricing of $45.0 million Underwritten Offering of Common Stock and Pre-Funded Warrants
4:59pm
that such certificates have been acquired by a bona fide purchaser and, at the Company’s or the Warrant Agent’s request, reimbursement to the Company and the Warrant
425
tuirudgo fn988vf
15 Sep 22
Business combination disclosure
4:08pm
8-K
EX-99.1
d7low2479d8ild
15 Sep 22
Departure of Directors or Certain Officers
4:06pm
424B3
c33h3u6f4cv88om
8 Aug 22
Prospectus supplement
5:47pm
S-4
EX-10.5
8v9ztvvvct07t2 4bmz
18 Jul 22
Registration of securities issued in business combination transactions
7:58am
S-4
yvj0pn u147otyvbqhwa
18 Jul 22
Registration of securities issued in business combination transactions
7:58am
425
ux3oa r65xjewk2zk
5 Jul 22
Business combination disclosure
7:14am
8-K
EX-4.1
hh7t31humktx8m2dyom
5 Jul 22
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
7:07am
8-K
EX-2.1
xardsk7q
5 Jul 22
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
7:07am
8-K
EX-4.2
dkow3c7fz2azr04j99f
5 Jul 22
Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
7:07am